Publications
Below you can find a list of our published research.
Below you can find a list of our published research.
165 results
Cited 115 times since 2015 (13.4 per year) source: EuropePMC
Cell reports, Volume 13, Issue 4, 17 3 2015, Pages 733-745 Contractile Defect Caused by Mutation in MYBPC3 Revealed under Conditions Optimized for Human PSC-Cardiomyocyte Function. Birket MJ, Ribeiro MC, Kosmidis G, Ward D, Leitoguinho AR, van de Pol V, Dambrot C, Devalla HD, Davis RP, Mastroberardino PG, Atsma DE, Passier R, Mummery CL
Maximizing baseline function of human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) is essential for their effective application in models of cardiac toxicity and disease. Here, we aimed to identify factors that would promote an adequate level of function to permit robust single-cell contractility measurements in a human induced pluripotent stem cell (hiPSC) model of hypertrophic cardiomyopathy (HCM). A simple screen revealed the collaborative effects of thyroid hormone, IGF-1 and the... Abstract
Cited 4 times since 2015 (0.5 per year) source: EuropePMC
International journal of cardiology, Volume 202, 28 4 2015, Pages 571-572 Reduction of healthcare utilization after bone marrow cell therapy for refractory angina pectoris. Rodrigo SF, Mann I, van Ramshorst J, Beeres SL, Zwaginga JJ, Fibbe WE, Bax JJ, Schalij MJ, Atsma DE
Cited 18 times since 2015 (2 per year) source: EuropePMC
Circulation. Cardiovascular interventions, Volume 8, Issue 8, 1 1 2015, Pages e002740 Repeated Intramyocardial Bone Marrow Cell Injection in Previously Responding Patients With Refractory Angina Again Improves Myocardial Perfusion, Anginal Complaints, and Quality of Life. Mann I, Rodrigo SF, van Ramshorst J, Beeres SL, Dibbets-Schneider P, de Roos A, Wolterbeek R, Zwaginga JJ, Fibbe WE, Bax JJ, Schalij MJ, Atsma DE
Background: Intramyocardial bone marrow cell injection is associated with improvements in myocardial perfusion and anginal symptoms in patients with refractory angina pectoris. This study evaluates the effect of repeated intramyocardial bone marrow cell injection in patients with residual or recurrent myocardial ischemia. Methods and results: Twenty-three patients (17 men; 69±9 years) who had improved myocardial perfusion after the first injection but had residual or recurrent angina and ischemi... Abstract
Cited 9 times since 2015 (1 per year) source: EuropePMC
SpringerPlus, Volume 4, 10 2 2015, Pages 336 Myocardial infarction models in NOD/Scid mice for cell therapy research: permanent ischemia vs ischemia-reperfusion. van Zuylen VL, den Haan MC, Roelofs H, Fibbe WE, Schalij MJ, Atsma DE
Myocardial infarction animal studies are used to study disease mechanisms and new treatment options. Typically, myocardial infarction (MI) is induced by permanent occlusion of the left anterior descending artery. Since in MI patients coronary blood flow is often restored new experimental models better reflecting clinical practice are needed. Here, permanent ischemia MI (PI group) was compared with transient ischemia (45 min) (IR group) in immunodeficient NOD/Scid mice. Cardiac function, infarct... Abstract
Cited 31 times since 2015 (3.4 per year) source: EuropePMC
Journal of cardiovascular electrophysiology, Volume 26, Issue 5, 27 4 2015, Pages 547-555 QRS Fragmentation and QTc Duration Relate to Malignant Ventricular Tachyarrhythmias and Sudden Cardiac Death in Patients with Hypertrophic Cardiomyopathy. Debonnaire P, Katsanos S, Joyce E, VAN DEN Brink OV, Atsma DE, Schalij MJ, Bax JJ, Delgado V, Marsan NA
Background: QRS fragmentation (fQRS) and prolonged QTc interval on surface ECG are prognostic in various cardiomyopathies other than hypertrophic cardiomyopathy (HCM). The association between fQRS and prolonged QTc duration with occurrence of ventricular tachyarrhythmias or sudden cardiac death (VTA/SCD) in patients with HCM was explored. Methods and results: One hundred and ninety-five clinical HCM patients were studied. QTc duration was derived applying Bazett's formula; fQRS was defined... Abstract
Cited 215 times since 2015 (23.5 per year) source: EuropePMC
Circulation. Cardiovascular genetics, Volume 8, Issue 3, 27 4 2015, Pages 437-446 Clinical Presentation, Long-Term Follow-Up, and Outcomes of 1001 Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Patients and Family Members. Groeneweg JA, Bhonsale A, James CA, te Riele AS, Dooijes D, Tichnell C, Murray B, Wiesfeld AC, Sawant AC, Kassamali B, Atsma DE, Volders PG, de Groot NM, de Boer K, Zimmerman SL, Kamel IR, van der Heijden JF, Russell SD, Jan Cramer M, Tedford RJ, Doevendans PA, van Veen TA, Tandri H, Wilde AA, Judge DP, van Tintelen JP, Hauer RN, Calkins H
Background: Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is a progressive cardiomyopathy. We aimed to define long-term outcome in a transatlantic cohort of 1001 individuals. Methods and results: Clinical and genetic characteristics and follow-up data of ARVD/C index-patients (n=439, fulfilling of 2010 criteria in all) and family members (n=562) were assessed. Mutations were identified in 276 index-patients (63%). Index-patients presented predominantly with sustained ventric... Abstract
Cited 198 times since 2015 (21.4 per year) source: EuropePMC
Circulation research, Volume 116, Issue 8, 19 3 2015, Pages 1346-1360 Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Gyöngyösi M, Wojakowski W, Lemarchand P, Lunde K, Tendera M, Bartunek J, Marban E, Assmus B, Henry TD, Traverse JH, Moyé LA, Sürder D, Corti R, Huikuri H, Miettinen J, Wöhrle J, Obradovic S, Roncalli J, Malliaras K, Pokushalov E, Romanov A, Kastrup J, Bergmann MW, Atsma DE, Diederichsen A, Edes I, Benedek I, Benedek T, Pejkov H, Nyolczas N, Pavo N, Bergler-Klein J, Pavo IJ, Sylven C, Berti S, Navarese EP, Maurer G, ACCRUE Investigators
Rationale: The meta-Analysis of Cell-based CaRdiac study is the first prospectively declared collaborative multinational database, including individual data of patients with ischemic heart disease treated with cell therapy. Objective: We analyzed the safety and efficacy of intracoronary cell therapy after acute myocardial infarction (AMI), including individual patient data from 12 randomized trials (ASTAMI, Aalst, BOOST, BONAMI, CADUCEUS, FINCELL, REGENT, REPAIR-AMI, SCAMI, SWISS-AMI, TIME, LATE... Abstract
Cited 13 times since 2015 (1.4 per year) source: EuropePMC
Cardiovascular drugs and therapy, Volume 29, Issue 1, 1 1 2015, Pages 59-73 Post-myocardial infarct inflammation and the potential role of cell therapy. van Zuylen VL, den Haan MC, Geutskens SB, Roelofs H, Fibbe WE, Schalij MJ, Atsma DE
Myocardial infarction triggers reparative inflammatory processes programmed to repair damaged tissue. However, often additional injury to the myocardium occurs through the course of this inflammatory process, which ultimately can lead to heart failure. The potential beneficial effects of cell therapy in treating cardiac ischemic disease, the number one cause of death worldwide, are being studied extensively, both in clinical trials using adult stem cells as well as in fundamental research on car... Abstract
Cited 194 times since 2015 (20.8 per year) source: EuropePMC
European heart journal, Volume 36, Issue 14, 23 4 2015, Pages 847-855 Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers. Bhonsale A, Groeneweg JA, James CA, Dooijes D, Tichnell C, Jongbloed JD, Murray B, te Riele AS, van den Berg MP, Bikker H, Atsma DE, de Groot NM, Houweling AC, van der Heijden JF, Russell SD, Doevendans PA, van Veen TA, Tandri H, Wilde AA, Judge DP, van Tintelen JP, Calkins H, Hauer RN
Aims: We sought to determine the influence of genotype on clinical course and arrhythmic outcome among arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C)-associated mutation carriers. Methods and results: Pathogenic mutations in desmosomal and non-desmosomal genes were identified in 577 patients (241 families) from USA and Dutch ARVD/C cohorts. Patients with sudden cardiac death (SCD)/ventricular fibrillation (VF) at presentation (n = 36) were younger (median 23 vs. 36 years; P &... Abstract
Cited 108 times since 2014 (11.4 per year) source: EuropePMC
Proceedings of the National Academy of Sciences of the United States of America, Volume 111, Issue 50, 1 1 2014, Pages E5383-92 Recessive cardiac phenotypes in induced pluripotent stem cell models of Jervell and Lange-Nielsen syndrome: disease mechanisms and pharmacological rescue. Zhang M, D'Aniello C, Verkerk AO, Wrobel E, Frank S, Ward-van Oostwaard D, Piccini I, Freund C, Rao J, Seebohm G, Atsma DE, Schulze-Bahr E, Mummery CL, Greber B, Bellin M
Jervell and Lange-Nielsen syndrome (JLNS) is one of the most severe life-threatening cardiac arrhythmias. Patients display delayed cardiac repolarization, associated high risk of sudden death due to ventricular tachycardia, and congenital bilateral deafness. In contrast to the autosomal dominant forms of long QT syndrome, JLNS is a recessive trait, resulting from homozygous (or compound heterozygous) mutations in KCNQ1 or KCNE1. These genes encode the α and β subunits, respectively, of the ion c... Abstract
Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation, Volume 22, Issue 11, 1 1 2014, Pages 491-492 Image-guided intramyocardial cell injection: putting a puzzle piece in the right place. Ramkisoensing AA, Atsma DE
Cited 2 times since 2014 (0.2 per year) source: EuropePMC
Circulation research, Volume 115, Issue 4, 1 1 2014, Pages e6-7 Cardiac anisotropy, regeneration, and rhythm. Pijnappels DA, Schalij MJ, Atsma DE, de Vries AA
Cited 7 times since 2014 (0.7 per year) source: EuropePMC
International journal of cardiology, Volume 175, Issue 3, 2 1 2014, Pages 539-544 Predictors of response to intramyocardial bone marrow cell treatment in patients with refractory angina and chronic myocardial ischemia. Rodrigo SF, van Ramshorst J, Mann I, Leong DP, Cannegieter SC, Al Younis I, Dibbets-Schneider P, de Roos A, Fibbe WE, Zwaginga JJ, Bax JJ, Schalij MJ, Beeres SL, Atsma DE
Background: We previously showed that intramyocardial bone marrow cell (BMC) injection in patients with refractory angina and chronic myocardial ischemia improves myocardial perfusion, cardiac function and disease-related complaints. Treatment effect varied between patients, but the predictors of response remain to be identified. Therefore, the aim of the present study was to assess whether patient characteristics, procedural data and baseline measurements influence the response to intramyocardi... Abstract
Cited 42 times since 2014 (4.2 per year) source: EuropePMC
Journal of cellular and molecular medicine, Volume 18, Issue 8, 1 1 2014, Pages 1509-1518 Serum supplemented culture medium masks hypertrophic phenotypes in human pluripotent stem cell derived cardiomyocytes. Dambrot C, Braam SR, Tertoolen LG, Birket M, Atsma DE, Mummery CL
It has been known for over 20 years that foetal calf serum can induce hypertrophy in cultured cardiomyocytes but this is rarely considered when examining cardiomyocytes derived from pluripotent stem cells (PSC). Here, we determined how serum affected cardiomyocytes from human embryonic- (hESC) and induced pluripotent stem cells (hiPSC) and hiPSC from patients with hypertrophic cardiomyopathy linked to a mutation in the MYBPC3 gene. We first confirmed previously published hypertrophic effects of... Abstract
Cited 10 times since 2014 (1 per year) source: EuropePMC
Experimental cell research, Volume 327, Issue 2, 13 2 2014, Pages 297-306 Strategies for rapidly mapping proviral integration sites and assessing cardiogenic potential of nascent human induced pluripotent stem cell clones. Dambrot C, Buermans HP, Varga E, Kosmidis G, Langenberg K, Casini S, Elliott DA, Dinnyes A, Atsma DE, Mummery CL, Braam SR, Davis RP
Recent methodological advances have improved the ease and efficiency of generating human induced pluripotent stem cells (hiPSCs), but this now typically results in a greater number of hiPSC clones being derived than can be wholly characterized. It is therefore imperative that methods are developed which facilitate rapid selection of hiPSC clones most suited for the downstream research aims. Here we describe a combination of procedures enabling the simultaneous screening of multiple clones to det... Abstract
Cited 14 times since 2014 (1.4 per year) source: EuropePMC
Cardiovascular research, Volume 102, Issue 2, 27 4 2014, Pages 224-231 Interaction between myofibroblasts and stem cells in the fibrotic heart: balancing between deterioration and regeneration. Ramkisoensing AA, de Vries AA, Atsma DE, Schalij MJ, Pijnappels DA
Signalling between the various cell types in the heart has been investigated for decades. However, relatively little is known about the interplay between the cardiac fibroblasts and myofibroblasts, which help to maintain myocardial tissue structure and function, and resident cardiac or extracardiac stem cells involved in tissue homeostasis and repair. Much of our knowledge about these interactions is derived from experimental animal models, especially those of myocardial infarction and stem cell... Abstract
Cited 35 times since 2014 (3.4 per year) source: EuropePMC
The international journal of cardiovascular imaging, Volume 30, Issue 3, 6 1 2014, Pages 549-558 Global longitudinal strain and left atrial volume index improve prediction of appropriate implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy patients. Debonnaire P, Thijssen J, Leong DP, Joyce E, Katsanos S, Hoogslag GE, Schalij MJ, Atsma DE, Bax JJ, Delgado V, Marsan NA
Accurate predictors of appropriate implantable cardioverter defibrillator (ICD) therapy in hypertrophic cardiomyopathy (HCM) patients are lacking. Both left atrial volume index (LAVI) and global longitudinal strain (GLS) have been proposed as prognostic markers in HCM patients. The specific value of LAVI and GLS to predict appropriate ICD therapy in high-risk HCM patients was studied. LAVI and 2-dimensional speckle tracking-derived GLS were assessed in 92 HCM patients undergoing ICD implantation... Abstract
Cited 5 times since 2014 (0.5 per year) source: EuropePMC
The international journal of cardiovascular imaging, Volume 30, Issue 3, 31 5 2014, Pages 583-589 Effect of intramyocardial bone marrow-derived mononuclear cell injection on cardiac sympathetic innervation in patients with chronic myocardial ischemia. van Ramshorst J, Beeres SL, Rodrigo SF, Dibbets-Schneider P, Scholte AJ, Fibbe WE, Zwaginga JJ, Schalij MJ, Bax JJ, Atsma DE
Intramyocardial bone marrow cell injection has been associated with improvements in myocardial perfusion and left ventricular function. The current substudy of a randomized, placebo-controlled, double-blinded study, investigated the effect of intramyocardial bone marrow cell injection on myocardial sympathetic innervation in patients with chronic myocardial ischemia. In a total of 16 patients (64 ± 8 years, 13 men), early and late iodine-123 metaiodobenzylguanidine (MIBG) imaging was performed b... Abstract
Cited 67 times since 2013 (6.2 per year) source: EuropePMC
Journal of cardiovascular translational research, Volume 6, Issue 5, 28 4 2013, Pages 816-825 Intramyocardial injection of autologous bone marrow-derived ex vivo expanded mesenchymal stem cells in acute myocardial infarction patients is feasible and safe up to 5 years of follow-up. Rodrigo SF, van Ramshorst J, Hoogslag GE, Boden H, Velders MA, Cannegieter SC, Roelofs H, Al Younis I, Dibbets-Schneider P, Fibbe WE, Zwaginga JJ, Bax JJ, Schalij MJ, Beeres SL, Atsma DE
In experimental studies, mesenchymal stem cell (MSC) transplantation in acute myocardial infarction (AMI) models has been associated with enhanced neovascularization and myogenesis. Clinical data however, are scarce. Therefore, the present study evaluates the safety and feasibility of intramyocardial MSC injection in nine patients, shortly after AMI during short-term and 5-year follow-up. Periprocedural safety analysis demonstrated one transient ischemic attack. No other adverse events related t... Abstract
Cited 28 times since 2013 (2.6 per year) source: EuropePMC
The American journal of cardiology, Volume 112, Issue 8, 19 3 2013, Pages 1197-1206 Arrhythmogenic right ventricular dysplasia/cardiomyopathy according to revised 2010 task force criteria with inclusion of non-desmosomal phospholamban mutation carriers. Groeneweg JA, van der Zwaag PA, Olde Nordkamp LR, Bikker H, Jongbloed JD, Jongbloed R, Wiesfeld AC, Cox MG, van der Heijden JF, Atsma DE, de Boer K, Doevendans PA, Vink A, van Veen TA, Dooijes D, van den Berg MP, Wilde AA, van Tintelen JP, Hauer RN
Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is frequently associated with desmosomal mutations. However, nondesmosomal mutations may be involved. The aim of this study was to assess the contribution of a phospholamban (PLN) gene mutation to ARVD/C diagnosis according to the revised 2010 task force criteria (TFC). In 142 Dutch patients (106 men, mean age 51 ± 13 years) with proven ARVD/C (fulfillment of 2010 TFC for diagnosis), 5 known desmosomal genes (PKP2, DSP, DSC2, DSG... Abstract